BHCM
CTNM

Brevan Howard Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Brevan Howard Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$551K Buy
42,178
+22,752
+117% +$305K ﹤0.01% 1240
2025
Q4 		$222K Buy
+19,426
New +$222K ﹤0.01% 1527

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brevan Howard Capital Management's CTNM Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Contineum Therapeutics (CTNM) stake by 117% in Q1 2026, buying an estimated $305K and bringing the position to 42,178 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Brevan Howard Capital Management first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Brevan Howard Capital Management held 42,178 shares of Contineum Therapeutics worth $551K as of Q1 2026.
  • Brevan Howard Capital Management bought 22,752 Contineum Therapeutics shares in Q1 2026, an estimated $305K.
  • Contineum Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1240 holding.
  • Brevan Howard Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.